Evidence map›Paper›PMID 33063469›Full record

ArticleCancer medicine2020

Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center.

Jennifer A Weiss, Andrew Nicklawsky, Jodi A Kagihara, Dexiang Gao, Christine Fisher, Anthony Elias, Virginia F Borges, Peter Kabos, Sarah L Davis, Stephen Leong and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jennifer A WeissUniversity of Colorado School of Medicine, Aurora, CO, USA.ORCID 0000-0001-6877-6006
Andrew NicklawskyUniversity of Colorado School of Medicine, Aurora, CO, USA.
Jodi A KagiharaDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0001-8379-961X
Dexiang GaoUniversity of Colorado School of Medicine, Aurora, CO, USA.
Christine FisherDepartment of Radiation Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Anthony EliasDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Virginia F BorgesDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Peter KabosDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Sarah L DavisDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Stephen LeongDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Sue Gail EckhardtDivision of Medical Oncology, Dell Medical School, University of Texas at Austin, Austin, TX, USA.
Jennifer R DiamondDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Cell Immunotherapy and Experimental Therapeutics Program (CIETP).T32CA236734 · NCI · UNIVERSITY OF COLORADO DENVER · PI Eduardo V Davila, Antonio Jimeno · 2019 to 2026
$2.0M
The Development of Novel Individualized Therapy for Triple-Negative Breast CancerK23CA172691 · NCI · UNIVERSITY OF COLORADO DENVER · PI DIAMOND, JENNIFER R. · 2013 to 2017
$859k
NCI NIH HHS K23 CA172691NCI NIH HHS P30 CA046934NCI NIH HHS T32 CA236734
6 · The paper itself

Abstract

Patients with metastatic breast cancer (MBC) refractory to standard of care therapies have a poor prognosis. The purpose of this study was to assess patient characteristics and clinical outcomes for patients with MBC treated on phase I clinical trials. We performed a retrospective review of all patients with MBC who were enrolled in phase I clinical trials at the University of Colorado Cancer Center from January 2012 to June 2018. A total of 208 patients were identified. Patients had a mean age of 57 years and received on average 2.1 (range 0-10) prior lines of chemotherapy. The majority of patients had hormone receptor-positive/HER2-negative breast cancer (58.6%) and 30.3% had triple-negative breast cancer. The median progression free survival (PFS) was 2.8 months (95% CI, 2.3-3.9) and median overall survival (OS) was 11.5 months (95% CI, 9.6-13.2). Independent factors associated with longer PFS in multivariable analysis were treatment in a breast cancer-selective trial or cohort (p = 0.016), age >50 years (p = 0.002), and ≤2 prior lines of chemotherapy in the metastatic setting (p = 0.025). Phase I clinical trials remain a valuable option for select patients with MBC and enrollment should be encouraged when available.

Indexed as

Cancer Care FacilitiesAdultAgedAged, 80 and overBreast NeoplasmsClinical Trials, Phase I as TopicColoradoFemaleHumansMiddle AgedNeoplasm MetastasisProgression-Free SurvivalRetrospective StudiesRisk AssessmentRisk FactorsTime Factorsimmunotherapymetastatic breast cancerphase I clinical trialstargeted therapies

Identifiers

PMID33063469
PMCPMC7724484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.